Drug Trial Radar · NCT07935889
Advanced Imaging-Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma, SAGA 2.0 Trial
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
292
Planned (sponsor's estimate)
Start
Nov 13, 2026
Primary completion
Nov 30, 2035
Study completion Nov 30, 2035
Sponsor
- Lead sponsor
- Mayo ClinicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial studies how well advanced imaging-guided standard dose versus (vs.) dose-intensified radiation therapy (RT) and dose-intensified accelerated RT works in treating patients with newly diagnosed glioblastoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. During dose-intensified RT, a higher dose than normal of radiation therapy is delivered over 6 weeks. During dose-intensified accelerated RT, the higher dose of radiation therapy is delivered over a shorter amount of time (2 weeks) than normal (6 weeks). Patients also undergo an advanced brain imaging positron emission tomography (PET)/computed tomography (CT) scan (using a radioactive drug called either FET or FDOPA) prior to RT to that may help doctors better plan the treatment. Dose-intensified and dose-intensified accelerated radiation therapy may be effective in treating patients with newly diagnosed glioblastoma. Giving dose-intensified RT or dose-intensified accelerated RT guided by advanced imaging may work better than standard dose RT in treating patients with newly diagnosed glioblastoma. IND Numbers: 61300, 140882, 176402, 154793, 167879
Conditions
- Glioblastoma, IDH-Wildtype
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Computed TomographyProcedure
Undergo FET or FDOPA PET/CT
F-18 FluoroethyltyrosineRadiation
Given via injection
Fluorodopa F 18Drug
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
Dose-intensified Photon Beam Radiation TherapyRadiation
Undergo dose-intensified photon radiation therapy
Standard Photon Beam Radiation TherapyRadiation
Undergo standard photon radiation therapy
Dose-intensified Accelerated Photon Beam Radiation TherapyRadiation
Undergo dose-intensified accelerated photon radiation therapy
Accelerated Photon Beam Radiation TherapyRadiation
Undergo accelerated photon radiation therapy
Positron Emission TomographyProcedure
Undergo FET or FDOPA PET/CT
Proton Beam Radiation TherapyRadiation
Undergo dose-intensified proton radiation therapy
Proton Beam Radiation TherapyRadiation
Undergo standard proton radiation therapy
Proton Beam Radiation TherapyRadiation
Undergo dose-intensified accelerated proton radiation therapy
Proton Beam Radiation TherapyRadiation
Undergo accelerated proton radiation therapy
Questionnaire AdministrationOther
Ancillary studies
TemozolomideDrug
Given SOC temozolomide
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (Cohort 1)Time frame: Up to 18 months
- Overall survival (Cohort 2)Time frame: Up to 12 months
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Arizona
Scottsdale, Arizona · Not yet recruiting
Mayo Clinic in Florida
Jacksonville, Florida · Not yet recruiting
Mayo Clinic Health System in Albert Lea
Albert Lea, Minnesota · Recruiting
Mayo Clinic Health Systems-Mankato
Mankato, Minnesota · Recruiting
Mayo Clinic Radiation Therapy - Northfield
Northfield, Minnesota · Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota · Recruiting
Mayo Clinic Health System-Eau Claire Clinic
Eau Claire, Wisconsin · Recruiting
Mayo Clinic Health System-Franciscan Healthcare
La Crosse, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.